Terminated PHASE1/PHASE2 INTERVENTIONAL NCT00284531

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100

Sponsor: Baylor College of Medicine

Conditions Cardiac Transplantation

Interventions Daclizumab

Updated 6 times since 2017 Last updated: Oct 14, 2015 Started: Oct 31, 2003 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

Other terminated trials from Baylor College of Medicine

See all terminations from Baylor College of Medicine

Listed as NCT00284531, this PHASE1/PHASE2 trial focuses on Cardiac Transplantation and remains terminated or withdrawn. Sponsored by Baylor College of Medicine, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine
Roche Pharma AG

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States